

**Lipa Pharmaceuticals Ltd and Optigen Ingredients Pty. Ltd.**

**MoU – Supply Chain Agreement  
September 2014**

Lipa Pharmaceuticals Ltd. (Lipa) and Optigen Pty. Ltd. (Optigen) have signed a ground breaking Memorandum of Understanding (MoU) that improves and defines their ongoing raw material and ingredients supply chain relationship.

In essence, Lipa have undertaken to purchase a substantive volume of raw materials and ingredients from Optigen over an agreed period of time.

Optigen have undertaken to supply these raw materials and ingredients on the basis of a range of key criteria inclusive of specific Quality, Service and Value deliverables.

High quality and competitively priced raw materials and ingredients are the primary drivers of finished product costs in the local Australian and Export markets.

The MoU provides Lipa and Optigen the opportunity and flexibility to better service their respective clients and stakeholders through a range of initiatives based on combined volume purchases and optimised warehousing and distribution activities.

Joint Statement by and on behalf of:



Dusko Pejnovic  
Chief Executive Officer  
Lipa Pharmaceuticals Ltd  
[www.lipa.com.au](http://www.lipa.com.au)



David Leister  
General Manager  
Optigen Ingredients Pty Ltd  
[www.optigen.com.au](http://www.optigen.com.au)